The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Ruxolitinib for treatment of CRS in R/R AML treated with flotetuzumab
John DiPersio, MD, PhD, Washington University School of Medicine, Saint Louis, MO, outlines the results of a study investigating prophylactic ruxolitinib for the treatment of cytokine release syndrome (CRS) in relapsed/refractory (R/R) acute myeloid leukemia (AML) patients treated with flotetuzumab. The study found that prophylactic ruxolitinib produced a clear difference in cytokine profiles but no discernible improvement in clinical CRS or response rates. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
